"FDA Commissioner Stephen Hahn, M.D., has vowed to permanently adopt COVID-19-driven changes that make reviews and authorizations faster. Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development."
“To the extent that innovations and adaptations we implemented during the pandemic crisis worked and would be appropriate to implement outside of a pandemic situation, we will incorporate them into standard FDA procedures. And to the extent that we identified unnecessary barriers, we will remove them. This is one of my top priorities. Permanent change, where needed, will take place,” Hahn said. "
... “In facilitating the development of new treatments, we streamlined some of our processes. Anything that enables quicker reviews and authorizations, we will seek to make permanent,” Hahn said.The pandemic could also lead to lasting changes in how drug developers gather evidence to support submissions to the FDA. Hahn identified decentralized clinical trials and real-world data as two areas that could be turbocharged by the pandemic."
PAR Price at posting:
$3.18 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)